NTU Singapore scientists design compound that targets enzyme linked to autoimmune disorders and severe COVID-19



Published on : 12-Mar-2021

Scientists from NTU Singapore have created a compound that could help to reduce the body’s immune response overactivation without impairing its entire reaction, including when fighting COVID-19.

​Media reports

Bioengineer (UK), 10 Mar
Phys.org (US), 10 Mar
The Medical News (Australia), 10 Mar
Tech Xplorist (India), 10 Mar
BioSpectrum Asia, 11 Mar
World Pharma News (Denmark), 10 Mar
Drug Target Review (UK), 11 Mar 
Lab Manager (US), 12 Mar
Hospimedica (UK), 15 Mar
Tencent News (China), 14 Mar
Bio1000 (China), 14 Mar
eBiotrade (China), 15 Mar

News release


Printer-friendly | Send to a friend